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Objectives
At the conclusion of this session, the participant will be 
able to:
 Describe the evidence for the benefits and harms of opioid 
therapy for chronic pain outside of active cancer treatment, 
palliative, and end-of-life care.
 Review methods for setting goals for pain management with 
patients.
 Summarize factors that increase risk for harm and how to 
assess for such factors.
 Review methods for assessing patients’ pain and function, and 
for conducting appropriate follow-up.
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Difficult to predict benefits and harms of long-
term opioid use in individual patients 
• Unclear whether there are long-term benefits 
• Short-term benefits 
– Small to moderate for pain
– Inconsistent for function
• Serious risks include opioid use disorder and overdose
• Risk assessment instruments do not consistently predict 
opioid abuse or misuse
Opioids not first-line or routine
therapy for chronic pain
• Nonpharmacologic therapy and nonopioid pharmacologic 
therapy are preferred for chronic pain. 
• Clinicians should consider opioid therapy only if expected 
benefits for both pain and function are anticipated to 
outweigh risks to the patient. 
• If opioids are used, they should be combined with 
nonpharmacologic therapy and nonopioid pharmacologic 
therapy, as appropriate. 
(Recommendation category: A; Evidence type: 3)
Establish and measure progress
toward goals
• Before starting opioid therapy for chronic pain, clinicians 
should establish treatment goals with all patients, 
including realistic goals for pain and function, and should 
consider how therapy will be discontinued if benefits do 
not outweigh risks. 
• Clinicians should continue opioid therapy only if there is 
clinically meaningful improvement in pain and function 
that outweighs risks to patient safety. 
(Recommendation category: A; Evidence type: 4)
Before starting long-term opioids for chronic 
pain
1. Determine whether expected benefits for both pain and 
function are anticipated to outweigh risks to the patient 
2. Establish treatment goals* 
3. Set criteria for stopping or continuing opioids 
4. Have an “exit strategy” for discontinuing therapy
*For patients already receiving opioids, establish goals for continued treatment
Assessing likely benefits of opioid therapy for 
individual patients
• Consider diagnosis (insufficient evidence for long-term 
benefits in headache, fibromyalgia, nonspecific back pain)
• Consider patient goals
– Opioids might reduce pain in the short term 
– Opioids might reduce intermittent exacerbations of pain 
– Opioids might not reduce pain effectively long term
– Opioids unlikely to eliminate pain 
– No demonstrated long-term improvement in function
Evaluate and address risks for 
opioid-related harms
• Before starting and periodically during continuation of 
opioid therapy, clinicians should evaluate risk factors for 
opioid-related harms. 
• Clinicians should incorporate into the management plan 
strategies to mitigate risk, including considering offering 
naloxone when factors that increase risk for opioid 
overdose, such as history of overdose, history of substance 
use disorder, higher opioid dosages (>50 MME/day), or 
concurrent benzodiazepine use, are present. 
(Recommendation category: A; Evidence type: 4)
Assessing for mental health conditions
• Treatment for depression may decrease overdose risk when 
opioids are used
• Assess for anxiety, PTSD, and depression using validated 
tools, e.g., 
– Generalized Anxiety Disorder (GAD)-7 
– Patient Health Questionnaire (PHQ)-9
– PHQ-4 
Assessing for substance use disorder
• Ask patients about their drug and alcohol use 
– Single screening questions can be used, e.g., “How many 
times in the past year have you used an illegal drug or 
used a prescription medication for nonmedical reasons?” 
– Validated screening tools can also be used, e.g., 
• Drug Abuse Screening Test (DAST) 
• Alcohol Use Disorders Identification Test (AUDIT) 
• Use PDMP data and urine drug testing to assess for 
concurrent substance use 
Establishing treatment goals
• Include goals for both pain and function
– Improvement in physical function not always realistic 
(e.g., catastrophic spinal injury) 
– Function can include emotional and social dimensions 
• Set realistic, meaningful functional goals 
(e.g., walk around block) 
• Set goals for objective improvement
• Use validated instruments such as the PEG* Assessment Scale 
– Clinically meaningful improvement: >30% improvement 
* Pain average, interference with Enjoyment of life, and interference with General 
activity (PEG) Assessment Scale 
3-item  (PEG) Assessment Scale
1. What number best describes your pain on average in the 
past week? (from 0=no pain to 10=pain as bad as you can 
imagine) 
2. What number best describes how, during the past week, 
pain has interfered with your enjoyment of life? (from 
0=does not interfere to 10=completely interferes) 
3. What number best describes how, during the past week, 
pain has interfered with your general activity? (from 
0=does not interfere to 10=completely interferes)
PEG = Pain average, interference with Enjoyment of life, 
and interference with General activity
Re-evaluate benefits and harms 
of opioids, and continue therapy 
only as a deliberate decision
• Clinicians should evaluate benefits and harms with 
patients within 1 to 4 weeks of starting opioid therapy for 
chronic pain or of dose escalation. 
• Clinicians should evaluate benefits and harms of 
continued therapy with patients every 3 months or more 
frequently. 
• If benefits do not outweigh harms of continued opioid 
therapy, clinicians should optimize other therapies and 
work with patients to taper opioids to lower dosages or to 
taper and discontinue opioids.
(Recommendation category: A; Evidence type: 4)
How often to evaluate patients to assess 
benefits and harms of long-term opioid use?
• Within 1 - 4 weeks of starting or increasing dosage 
– Within 1 week when 
• Starting or increasing ER/LA opioids 
• Total daily opioid dosage >50 MME/day 
– Within 3 days when starting or increasing methadone 
• Regularly reassess at least every 3 months 
• Reassess patients exposed to greater risk more frequently
– Depression or other mental health conditions 
– History of substance use disorder or overdose 
– Taking ≥50 MME/day or other CNS depressants
Before continuing long-term opioids for chronic 
pain, ask
• Do opioids continue to meet treatment goals?
– Progress toward individual patient goals?
– Sustained, meaningful improvement in pain and function? 
• Are there adverse events or early warning signs? 
– Over-sedation or overdose risk  (if yes, taper dose)
– Signs of opioid use disorder (if yes, treat or refer)
• Do benefits continue to outweigh risks?
• Can dosage can be reduced?
• Can opioids can be discontinued?
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ASSESSING ENEFITS AND HARMS 
OF OPIOID THERAPY
• Ms. Christie is a 46 year old woman who has 
had fibromyalgia for the past three years. She 
was sent by her primary care provider to a 
rheumatologist who diagnosed fibromyalgia 
after a physical exam and an extensive series 
of blood tests.
• Her primary care provider treated her with 
gabapentin 300mg qAM and 600mg qHS with 
moderately good results. She continued to 
have moderate 5/10 pain, but she was able to 
continue her job as a receptionist and her role 
as wife and mother to two high-school 
students.
CASE: 46 YR OLD WOMAN WITH FM
Opioids not first-line or routine
therapy for chronic pain
• Nonpharmacologic therapy and nonopioid pharmacologic 
therapy are preferred for chronic pain. 
• Clinicians should consider opioid therapy only if expected 
benefits for both pain and function are anticipated to 
outweigh risks to the patient. 
• If opioids are used, they should be combined with 
nonpharmacologic therapy and nonopioid pharmacologic 
therapy, as appropriate.
(Recommendation category: A; Evidence type: 3)
• “Evidence is insufficient to determine the 
effectiveness of long-term opioid therapy for 
improving chronic pain and function. Evidence 
supports a dose-dependent risk for serious 
harms.”
• Chou R et al Annals Intern Med 2015; 
162:276-86
NATIONAL INSTITUTES OF HEALTH 
PATHWAYS TO PREVENTION WORKSHOP
• Opioid analgesics are commonly used for 
the treatment of fibromyalgia (FM) despite 
multiple treatment guidelines that 
recommend against the use of long-term 
opioid therapy
• American Pain Society and the American 
Academy of Pain Medicine 
• American Academy of Neurology 
• European League Against Rheumatism 
• Canadian Pain Society and the Canadian 
Rheumatology Association 
• British Pain Society
OPIOID TREATMENT OF FIBROMYALGIA
• Cochrane 2014 review concludes there is “no 
evidence at all” of oxycodone efficacy 
for fibromyalgia
• Tramadol may be effective in the treatment of 
FM but it is a weak opioid receptor agonist, 
and its efficacy in FM is likely related to its  
action as a serotonin-norepinephrine reuptake 
inhibitor.
OPIOID TREATMENT OF FIBROMYALGIA 
• Three months before today’s visit, Ms. Christie was 
rear-ended when stopped at a stoplight. She 
suffered a significant exacerbation of her 
fibromyalgia. She reported severe 8/10 pain in the 
ED immediately after the crash. She had no 
fractures, but was diagnosed with neck and back 
sprain. At that time she was prescribed oxycodone 
5mg every 4 hours as needed for pain.
• She continued to complain of severe 7/10 
widespread pain despite taking 20mg oxycodone 
when she saw her primary care provider 2 weeks 
after the crash. Furthermore, she said that she 
was no longer able to do her job or fulfill her 
responsibilities at home.
CASE: 46 YEAR OLD WOMAN WITH FM
Establish and measure progress
toward goals
• Before starting opioid therapy for chronic pain, clinicians 
should establish treatment goals with all patients, 
including realistic goals for pain and function, and should 
consider how therapy will be discontinued if benefits do 
not outweigh risks. 
• Clinicians should continue opioid therapy only if there is 
clinically meaningful improvement in pain and function 
that outweighs risks to patient safety. 
(Recommendation category: A; Evidence type: 4)
She asked her primary care provider to 
increase her oxycodone dose to improve 
her pain and function level. Her primary 
care provider wanted to help her keep her 
job, so he wrote for oxycodone ER 20mg 
twice a day. When he checked in with her 
a week later, she reported feeling better 
and was getting back to work.
CASE: 46 YR OLD WOMAN WITH FM 
• It is best to establish goals before embarking 
on a course of long-term opioid therapy, 
including criteria of success and failure
www.coperems.org
• Focus on achievement of life goals. Do not 
accept the goal of “no pain” or the goal of 
“less pain” in isolation from life goals
• If patient resists, ask “ how would your life be 
different if you had significantly less pain?” 
Then explain that this is the life you will aim 
for together, which may or may not involve 
significant pain reduction.
ESTABLISHING GOALS FOR OPIOID 
THERAPY FOR CHRONIC PAIN
• Measuring pain intensity alone is not 
adequate 
• wrong goals 
• wrong patients
• wrong understanding
• Need multidimensional assessment
• Function, both physical and role, personal 
activity
• Sleep, depression, anxiety
• Is life moving forward again?
• http://paintracker.uwmedicine.org
MEASURING PROGRESS 
IN CHRONIC PAIN CARE
Re-evaluate benefits and harms 
of opioids, and continue therapy 
only as a deliberate decision
• Clinicians should evaluate benefits and harms with 
patients within 1 to 4 weeks of starting opioid therapy for 
chronic pain or of dose escalation. 
• Clinicians should evaluate benefits and harms of 
continued therapy with patients every 3 months or more 
frequently. 
• If benefits do not outweigh harms of continued opioid 
therapy, clinicians should optimize other therapies and 
work with patients to taper opioids to lower dosages or to 
taper and discontinue opioids.
(Recommendation category: A; Evidence type: 4)
• Short-term and long-term opioid therapy are 
different therapies, even if same meds used
• Short-term response (weeks-months) does not 
predict long-term response (months-years)
• Patients themselves tend to overestimate the 
benefit of therapy based on experiences with 
starting and stopping opioid therapy
• Pay attention to patients’ report of current 
level of pain and function, but don’t be 
distracted by claims that “I would be much 
worse without these opioids”
MEASURING PROGRESS IN RESPONSE TO 
LONG-TERM OPIOID THERAPY
Evaluate and address risks for 
opioid-related harms
• Before starting and periodically during continuation of 
opioid therapy, clinicians should evaluate risk factors for 
opioid-related harms. 
• Clinicians should incorporate into the management plan 
strategies to mitigate risk, including considering offering 
naloxone when factors that increase risk for opioid 
overdose, such as history of overdose, history of substance 
use disorder, higher opioid dosages (>50 MME/day), or 
concurrent benzodiazepine use, are present. 
(Recommendation category: A; Evidence type: 4)
• Medication regimen
• Opioid dose
• Long-acting or extended-release opioids
• Concurrent sedative use
• Patient characteristics
• Current or past substance use disorders (tobacco)
• Inadequately treated mental health disorders (PTSD)
• Young age
• Previous opioid overdose
TWO SOURCES OF RISK 
FOR LONG-TERM OPIOID THERAPY
• Decreased function/return to work (cohorts)
• Hyperalgesia
• Tolerance (invisible?)
• Dependence (lifelong?) 
• Misuse (due to above)
• Abuse (25%) and addiction (10%)
RISKS OF LONG-TERM OPIOID THERAPY
TO PATIENTS
• Hypogonadism (infertility, low libido)
• Masked psychiatric disorder (PTSD)
• Induced depression (duration > dose)
• Overdose, death, emergency department visits 
(>700,000 in 2012)
• Motor vehicle crashes (OR=1.2-1.5)
• Falls, fractures, sedation, delirium
RISKS OF LONG-TERM OPIOID THERAPY 
TO PATIENTS
• Abuse 
o 12th graders: 10% 2010  6% 2014
• Accidental overdose, death 
oHeroin deaths doubled 2010 – 2012 
• Addiction
RISKS OF LONG-TERM OPIOID THERAPY
TO FAMILY AND FRIENDS
• Initially managed on gabapentin, began opioids 
in emergency department after motor vehicle 
crash
• These were continued because of reports of 
continued severe pain and dysfunction
• Opioid therapy slipped from short-term to long-
term without explicit examination of goals, risks 
and benefits of long-term opioid therapy
BACK TO MS. CHRISTIE
46 Y/O FEMALE WITH FIBROMYALGIA
• Ms. Christie should not have been given more 
than 3-7 days of opioids for her back strain from 
motor vehicle crash
• When she saw her primary care provider 2 
weeks later, her opioid therapy was now treating 
her FM, not her back strain from motor vehicle 
crash
• Her report of improvement a week after her 
primary care provider doubled her OxyContin 
dose, is not sounds promising, but is not a good 
indicator of her likelihood of benefit from long-
term therapy
BACK TO MS. CHRISTIE
46 Y/O FEMALE WITH FIBROMYALGIA 
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To Ask a Question
 Using the Webinar System
 “Click” the Q&A tab at the top left of the webinar tool bar
 “Click”  in the white space
 “Type” your question
 “Click” ask
 On the Phone
 Press Star (*) 1 to enter the queue
 State your name
 Listen for the operator to call your name 
 State your organization and then ask your question
Thank you for joining!
Centers for Disease Control and Prevention 
Atlanta, Georgia
http://emergency.cdc.gov/coca 
Today’s webinar  will be archived
When:  A few days after the live call
What:  All call recordings (audio, webinar, and 
transcript)
Where:  On the COCA Call webpage 
http://emergency.cdc.gov/coca/calls/2016/callinfo_080316.asp
51
Continuing Education  for COCA Calls
All continuing education (CME, CNE, CEU, CECH, ACPE, CPH, and 
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Those who participated in today’s COCA Call and who wish to receive 
continuing education  should complete the online evaluation by 
September 2, 2016 with the course code WC2286. Those who will 
participate in the on demand activity and wish to receive continuing 
education should complete the online evaluation between September 3 , 
2016 and August 2, 2018 will use course code WD2286. 
Continuing education certificates can be printed immediately upon 
completion of your online evaluation. A cumulative transcript of all 
CDC/ATSDR CE’s obtained through the CDC Training & Continuing 
Education Online System will be maintained for each user. 
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 Presenters:
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